Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adaptive Biotechnologies Corporation (ADPT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, commercial-stage biotechnology company, Adaptive Biotechnologies uses these filings to report financial results, material agreements, and other significant corporate events related to its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Among the key documents are current reports on Form 8-K, which the company files to furnish earnings press releases and to describe material events. For example, Adaptive Biotechnologies has filed Form 8-K reports to present quarterly financial results, including segment revenue for its MRD and Immune Medicine businesses, and to disclose the termination of a Strategic Collaboration and License Agreement with Genentech, Inc. related to cancer cell therapy research and development. These filings may also outline expected accounting impacts, such as recognition of remaining non-cash revenue from prior collaboration payments.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for more detailed information on revenue composition, operating expenses, segment performance, risk factors, and management’s discussion and analysis. For a company like Adaptive Biotechnologies, these periodic reports help explain how its clonoSEQ MRD business and Immune Medicine programs contribute to overall results, as well as how it manages cash burn targets and investment in research and development.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight the main points of each filing. Users can quickly see which filings relate to earnings announcements, collaboration changes, or other material events, and can use the underlying documents to analyze ADPT’s financial condition, strategic focus, and progress in MRD and immune medicine initiatives.
Adaptive Biotechnologies President and COO Julie Rubinstein exercised stock options and sold shares in pre-planned transactions. She exercised options to acquire 29,444 shares of common stock at $7.27 per share, then sold 38,120 shares of common stock in open-market trades at weighted average prices of $14.45 and $14.60 per share.
All transactions were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025, indicating they were pre-scheduled. Following these trades, Rubinstein directly holds 447,202 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and related share sales in late March. She exercised stock options for 44,166 shares of common stock at an exercise price of $7.27 per share, then sold 57,180 shares of common stock in open-market transactions at prices in the $12–$13 range. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following the trades, she directly holds 455,878 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and related stock sales in common stock. Over March 24–26, she exercised stock options to acquire a total of 44,166 shares of common stock at an exercise price of $7.27 per share. She then sold 57,180 shares in open-market transactions at weighted average prices ranging from $13.45 to $14.49 per share. Following these transactions, she directly holds 468,892 shares of Adaptive Biotechnologies common stock. The filing notes that all transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.
The Vanguard Group filed Amendment No. 6 to a Schedule 13G/A reporting 0 shares (0%) of Adaptive Biotechnologies Corp common stock. The filing explains an internal realignment that disaggregated certain Vanguard subsidiaries' holdings in reliance on SEC Release No. 34-39538, so Vanguard reports no beneficial ownership here. The form is signed by Ashley Grim, Head of Global Fund Administration on 03/26/2026.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported a series of option exercises and share sales in March 2026. She exercised stock options to acquire a total of 44,166 shares of common stock at exercise prices of $6.55 and $7.27 per share, then sold 57,180 shares in open-market transactions.
The sales occurred in three equal blocks of 19,060 shares at weighted average prices of $13.18, $13.37 and $13.83 per share. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following these trades, Rubinstein directly holds 481,906 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies President and COO Julie Rubinstein reported an exercise-and-sell transaction pattern in company stock. Over three days, she exercised stock options to acquire a total of 44,166 shares of common stock at an exercise price of $6.55 per share.
She then sold 57,180 shares of common stock in open-market transactions at reported prices of $13.41, $13.40, and $13.18 per share, with each sale executed as multiple trades within disclosed price ranges. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.
Following these transactions, Rubinstein directly owned 494,920 shares of Adaptive Biotechnologies common stock, indicating she retained a substantial equity position after the option exercises and sales.
Reported registration to sell 18,672 restricted stock units under Rule 144. The filing lists the securities as Restricted Stock Units with an offering/filing date of 03/10/2026. The broker/filing agent is Morgan Stanley Smith Barney LLC.
Separately, the filing discloses prior open-market dispositions by Kyle Piskel: 2,145 shares sold on 02/04/2026 for $39,596.70 and 4,290 shares sold on 01/12/2026 for $77,220.00.
Adaptive Biotechnologies insider filing reports sales. The Form 144 lists 122,523 Restricted Stock Units to be sold with an effective date of 03/10/2026. The filing also details multiple sales by Julie Rubinstein between 03/03/2026 and 03/13/2026, showing individual trade sizes and proceeds.